Tracon Pharmaceuticals, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024096403 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $6.270M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.510M
YoY Change -40.77%
LONG-TERM ASSETS
Property, Plant & Equipment $30.00K
YoY Change -31.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $890.0K
YoY Change -25.77%
TOTAL ASSETS
Total Short-Term Assets $6.510M
Total Long-Term Assets $890.0K
Total Assets $7.400M
YoY Change -39.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.652M
YoY Change -83.64%
Accrued Expenses $6.823M
YoY Change 561.78%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.891M
YoY Change -63.47%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities $598.0K
YoY Change -30.14%
Total Long-Term Liabilities $598.0K
YoY Change -30.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.891M
Total Long-Term Liabilities $598.0K
Total Liabilities $10.49M
YoY Change -62.44%
SHAREHOLDERS EQUITY
Retained Earnings -$246.5M
YoY Change -2.07%
Common Stock $243.4M
YoY Change 3.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.089M
YoY Change
Total Liabilities & Shareholders Equity $7.400M
YoY Change -39.29%

Cashflow Statement

Concept 2024 Q3 2024 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001394319
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#CollaborativeArrangementMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#CollaborativeArrangementMember
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36818
dei Entity Registrant Name
EntityRegistrantName
TRACON Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
34-2037594
dei Entity Address Address Line1
EntityAddressAddressLine1
4350 La Jolla Village Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
550-0780
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
TCON
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3407564
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6270000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8564000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
240000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
526000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
6510000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9090000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
73000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
73000
CY2024Q2 us-gaap Other Assets
OtherAssets
787000
CY2023Q4 us-gaap Other Assets
OtherAssets
905000
CY2024Q2 us-gaap Assets
Assets
7400000
CY2023Q4 us-gaap Assets
Assets
10105000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2652000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2544000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6823000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7211000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
416000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
427000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9891000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10182000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
598000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
732000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3407564
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3407564
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2285818
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2285818
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
243414000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
239688000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-246506000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-240499000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-3089000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-809000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7400000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10105000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
155000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9000000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1350000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3488000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3228000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8457000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1617000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1916000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3051000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4260000
CY2023Q2 tcon Arbitration Success Fees
ArbitrationSuccessFees
4375000
tcon Arbitration Success Fees
ArbitrationSuccessFees
4375000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
2967000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
9779000
us-gaap Operating Expenses
OperatingExpenses
6279000
us-gaap Operating Expenses
OperatingExpenses
17092000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2912000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-779000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6124000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8092000
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
75000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-5507000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
128000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-6695000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
73000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5507000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
117000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6698000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2839000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6286000
us-gaap Net Income Loss
NetIncomeLoss
-6007000
us-gaap Net Income Loss
NetIncomeLoss
-14790000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.94
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.94
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.36
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3008090
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3008090
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1595892
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1595892
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2698454
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2698454
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1427579
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1427579
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-809000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
383000
CY2024Q1 tcon Issuances Of Common Stock Net Of Offering Costs Value
IssuancesOfCommonStockNetOfOfferingCostsValue
1832000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3168000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1762000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
339000
CY2024Q2 tcon Issuances Of Common Stock Net Of Offering Costs Value
IssuancesOfCommonStockNetOfOfferingCostsValue
1172000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2839000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-3089000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-7151000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
484000
CY2023Q1 tcon Issuances Of Common Stock And Warrants Net Of Offering Costs Value
IssuancesOfCommonStockAndWarrantsNetOfOfferingCostsValue
4099000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-8504000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-11072000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
502000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
502000
CY2023Q2 tcon Issuances Of Common Stock Net Of Offering Costs Value
IssuancesOfCommonStockNetOfOfferingCostsValue
1074000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
43000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6286000
CY2023Q2 us-gaap Shares Outstanding
SharesOutstanding
1403776
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-15739000
us-gaap Profit Loss
ProfitLoss
-6007000
us-gaap Profit Loss
ProfitLoss
-14790000
us-gaap Share Based Compensation
ShareBasedCompensation
722000
us-gaap Share Based Compensation
ShareBasedCompensation
986000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7000
tcon Interest Expense Noncash
InterestExpenseNoncash
88000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6656000
tcon Lease Asset Amortization And Liability Accretion Net
LeaseAssetAmortizationAndLiabilityAccretionNet
5000
tcon Lease Asset Amortization And Liability Accretion Net
LeaseAssetAmortizationAndLiabilityAccretionNet
12000
tcon Collaboration Receivable
CollaborationReceivable
-9000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-286000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-539000
tcon Increase Decrease In Accounts Payable And Accrued Expenses Excluding Accrued Compensation And Related Expenses
IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses
-314000
tcon Increase Decrease In Accounts Payable And Accrued Expenses Excluding Accrued Compensation And Related Expenses
IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAccruedCompensationAndRelatedExpenses
5074000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-11000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-426000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5312000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10854000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
10000000
tcon Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts
3017000
tcon Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts
5185000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
43000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3018000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4772000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2294000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15626000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8637000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17500000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6343000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1874000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-246500000
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
6300000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-twenty reverse stock split of its common stock (the Reverse Stock Split)
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s unaudited condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company’s unaudited condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue, and expenses. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to expenses incurred for clinical trials. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of this filing.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
CY2024Q2 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
192716
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
236244
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
6053000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
3616000
CY2024Q2 tcon Restricted Cash Fair Value Disclosure
RestrictedCashFairValueDisclosure
73000
CY2023Q4 tcon Restricted Cash Fair Value Disclosure
RestrictedCashFairValueDisclosure
73000
CY2024Q2 tcon Cash Equivalents Restricted Cash And Other Assets Fair Value Disclosure
CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure
6126000
CY2023Q4 tcon Cash Equivalents Restricted Cash And Other Assets Fair Value Disclosure
CashEquivalentsRestrictedCashAndOtherAssetsFairValueDisclosure
3689000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
0
CY2024Q2 tcon Fair Value Transfers Between Levels Amount
FairValueTransfersBetweenLevelsAmount
0
CY2023Q4 tcon Fair Value Transfers Between Levels Amount
FairValueTransfersBetweenLevelsAmount
0
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7807
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
339000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
502000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
722000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
986000

Files In Submission

Name View Source Status
0000950170-24-096403-index-headers.html Edgar Link pending
0000950170-24-096403-index.html Edgar Link pending
0000950170-24-096403.txt Edgar Link pending
0000950170-24-096403-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tcon-20240630.htm Edgar Link pending
tcon-20240630.xsd Edgar Link pending
tcon-ex31_1.htm Edgar Link pending
tcon-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
tcon-20240630_htm.xml Edgar Link completed